Bifogade filer
20241111_PM_Isofol_ASCO GI 2024 Accepted Abstract_Final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, SWEDEN, November 11, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT has been accepted by ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025.
The information in the press release is intended for investors.
ASCO GI 2025 is the annual meeting of the American Society of Clinical Oncology, focusing on gastrointestinal cancer. The congress gathers medical experts from all over the world and addresses the latest research that is deemed to have immediate impact on clinical practice within the field.
The abstract is prepared by an external expert group consisting of Göran Carlsson, MD, PhD, Sahlgrenska University Hospital; Åke Hjalmarson, MD, Prof in Cardiology at Sahlgrenska University Hospital, and Aldina Pivodic, PhD, APNC Sweden. It is based on the post-hoc per-protocol analysis of the global phase III-study AGENT conducted earlier this year and is funded by Isofol. The results show the importance of adherence to the study protocol and that a higher protocol compliance would likely increase the efficacy of arfolitixorin and thus, as previously communicated, support the company's new development plan.
Title: "The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial”.
Abstract no: 205
The abstract is published online, on January 21st at 16:00 CET and the poster is presented on site on January 25th at 07:00 PST.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 17:25 CET on November 11, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.